Poor
Needs Revision
Patient Risk:
Moderate
Summary
Several clinical/usage claims (motion sickness and PONV) are label-supported, and many listed adverse effects align with warnings/adverse reactions; however multiple claims are not supported by the provided label excerpts (e.g., treating GI/autonomic symptoms in general, contraindications framed as anticholinergic-burden, and multiple market/patent statements). Overall alignment is poor due to substantial unsupported content relative to the provided label.
Category Scores
Accurate Statements
Scopolamine is used for motion sickness prevention.
Section 1 INDICATIONS AND USAGE: prevention of nausea and vomiting associated with motion sickness in adults.
Scopolamine is used for prevention of postoperative nausea.
Section 1 INDICATIONS AND USAGE: post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.
Scopolamine has anticholinergic effects.
Section 12.1 Mechanism of Action: scopolamine is an anticholinergic.
Scopolamine can cause dry mouth.
Section 6.1 Clinical Trials Experience (Motion sickness): most common adverse reaction is dry mouth.
Scopolamine can cause blurred vision.
Section 5.6 Blurred Vision: temporary dilation of the pupils resulting in blurred vision if it comes in contact with the eyes.
Scopolamine can cause constipation.
Section 7.2 Anticholinergic Drugs: may increase risk of intestinal obstruction; and Section 12.1 notes decreased gastrointestinal motility (constipation/obstruction-related GI motility effects are consistent with this label content).
Scopolamine can cause drowsiness or confusion, especially in older adults.
Section 5.2 Neuropsychiatric Adverse Reactions: scopolamine can cause drowsiness, disorientation, and confusion; Section 8.5 Geriatric Use: elderly patients had increased risk of neurologic and psychiatric adverse reactions and consider more frequent monitoring.
Unsupported Statements
Scopolamine can be administered via transdermal or other routes.
Provided label excerpts describe scopolamine transdermal system and instructions for applying/removing the transdermal system, but do not support administration via other routes.
Scopolamine is used to treat certain gastrointestinal or autonomic-related symptoms, depending on local prescribing practices.
Provided label excerpts only support prevention indications for motion sickness nausea/vomiting and PONV; no label support is provided for treating other GI/autonomic symptoms.
Scopolamine use requires caution in patients with contraindications related to anticholinergic burden.
The provided label contraindications are angle closure glaucoma and hypersensitivity; the provided drug interaction section discusses concomitant anticholinergic drugs increasing risk, but the claim frames 'anticholinergic burden' contraindications in general and is not supported by the cited label excerpts.
Scopolamine's market/competitive landscape can depend on patent status and regulatory exclusivity for specific brands or formulations.
Not addressed in the provided FDA label excerpts (label content supplied concerns clinical use/safety rather than market/patent/regulatory exclusivity).
After key scopolamine protections expire, generics or competing versions can reduce prices and increase volume.
Not addressed in the provided FDA label excerpts.
When scopolamine branded products face generic competition, typical effects include lower unit prices.
Not addressed in the provided FDA label excerpts.
When scopolamine branded products face generic competition, typical effects include increased payer access and higher volumes.
Not addressed in the provided FDA label excerpts.
When scopolamine branded products face generic competition, prescribing may shift toward the lowest-cost available option depending on local formularies.
Not addressed in the provided FDA label excerpts.
Scopolamine competition can come from alternative antiemetics or motion-sickness therapies.
Not addressed in the provided FDA label excerpts.
Alternative antiemetics or motion-sickness therapies may displace scopolamine in some patients or settings based on side-effect profiles and clinician preference.
Not addressed in the provided FDA label excerpts.
Transdermal delivery is a major driver in scopolamine use cases for motion sickness and nausea-related use.
While the product described is a transdermal system, the provided label excerpts do not characterize 'major driver' or comparative drivers of use cases.
Different scopolamine formulations can affect ease of use, onset timing, adherence, and availability in different countries.
Not addressed in the provided FDA label excerpts.
Contradictions
Low
AI Statement
Scopolamine can be administered via transdermal or other routes.
Label Reference
Provided label excerpts specify scopolamine transdermal system and its application/removal; they do not support other administration routes. (No direct statement in excerpts that other routes are contraindicated; evaluated as unsupported rather than a direct contradiction.)
Important Omissions
No mention that scopolamine transdermal system is indicated specifically in adults for prevention of nausea/vomiting associated with motion sickness and PONV associated with recovery from anesthesia and/or opiate analgesia and surgery (and timing-specific dosing instructions).
Importance:
Moderate
No contraindication details are provided (angle closure glaucoma; hypersensitivity).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported expansion to 'other routes' and generalized treatment claims could mislead use. Multiple adverse effect statements align with label, but missing explicit contraindications and correct administration constraints reduce labeling fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Substantial unsupported claims (notably: other administration routes, treatment of other GI/autonomic symptoms, and all market/patent/competition statements) and omission of key label-specific constraints (adult-only prevention indications, explicit contraindications, and administration limitations).
Suggested Improvement
Restrict claims to FDA-label-supported indications (adult prevention of motion sickness nausea/vomiting and PONV) and describe administration only as the scopolamine transdermal system with label-specific application/removal instructions. Remove or segregate non-label market/patent/competition statements. Include contraindications (angle closure glaucoma; hypersensitivity) and avoid general 'anticholinergic burden' framing not present in the provided excerpts.